IL-9 Antibody Targeting Inflammatory Pathways
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for respiratory diseases, autoimmune diseases, and hematologic cancers are limited by their inability to effectively target and modulate the activity of interleukin-9 (IL-9), which plays a critical role in the pathogenesis of these conditions.
Innovation Solution
Development of an antibody specifically binding to IL-9, which includes specific heavy and light chain variable regions with defined complementarity-determining regions (CDRs), to selectively target and neutralize IL-9, thereby modulating its pathological effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If current therapies (NSAIDs, corticosteroids, immunosuppressants) are used for respiratory diseases and autoimmune diseases, then inflammatory symptoms can be controlled, but the disease progression cannot be altered and serious adverse reactions occur with long-term use
Solution Approach 1:
The patent extracts and targets the specific pathogenic mechanism by developing an antibody that specifically binds to IL-9, separating the treatment from non-specific immunosuppression. This allows selective neutralization of IL-9's harmful effects while preserving other immune functions, thereby reducing adverse reactions associated with broad immunosuppressants
Solution Approach 2:
The IL-9 antibody serves as a specific intermediary that blocks the interaction between IL-9 and its receptor, preventing the downstream inflammatory signaling cascade. This targeted mediation provides anti-inflammatory effects without the systemic side effects of traditional immunosuppressants
2Object-affected harmful factors
If current therapies are used for respiratory diseases and autoimmune diseases, then inflammatory symptoms can be controlled, but the natural progression of diseases is not altered and symptoms reappear upon discontinuation
Solution Approach 1:
By specifically targeting IL-9 as the extracted pathogenic factor, the antibody therapy addresses the root cause of disease progression rather than merely suppressing symptoms. This specific targeting provides more reliable and sustained control over disease progression compared to broad immunosuppression
Solution Approach 2:
The patent changes the therapeutic parameter from non-specific immunosuppression to specific IL-9 neutralization. This parameter change enables sustained disease modification by directly interfering with the IL-9 signaling pathway that drives chronic inflammation and tissue damage
3Reliability
If IL-9 antibody is developed to specifically target IL-9, then disease progression can be altered and adverse reactions reduced, but the complexity of antibody production and administration increases
Solution Approach 1:
The IL-9 antibody leverages the body's own immune system mechanisms to achieve therapeutic effects. By using a biologic molecule that naturally circulates in the body (antibody), the therapy achieves specific targeting and sustained action without requiring complex delivery systems or external control mechanisms
Data Source
AI summary
The present disclosure provides an antibody specifically binding to interleukin-9 (IL-9), a nucleic acid encoding the antibody, a vector including the nucleic acid, a host cell including the nucleic acid or the vector, a pharmaceutical composition including the antibody, and a use of the antibody and the pharmaceutical composition.